Today: 20 March 2026
Browse Category

NASDAQ:BENF 22 October 2025 - 9 December 2025

Biggest Stock Gainers Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and DBI Lead the After‑Bell Rally

Biggest Stock Gainers Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and DBI Lead the After‑Bell Rally

Aimei Health Technology shares surged 968% to $85.47 Tuesday after the SPAC extended its merger deadline to January 6, 2026, fueling speculation of a pending deal. The S&P 500 closed down 0.02%, while microcap stocks dominated gains, with Oriental Culture Holding up 321% and Netcapital up 122%. Trading in AFJK exceeded 6 million shares, far above its average.
Beneficient (BENF) Stock Skyrockets 64% After CEO Converts $52M Preferred into Common

Beneficient (BENF) Stock Skyrockets 64% After CEO Converts $52M Preferred into Common

Beneficient stock surged 64% to $0.80 after hours Oct. 21 following Chairman Thomas O. Hicks and Interim CEO James Silk converting $52.6 million of preferred units into Class A shares. The move aims to meet Nasdaq’s minimum equity rules after the company posted a Q1 FY2026 GAAP net loss of $7.19 per share. Zacks maintains a $2.00 price target, but ChartMill rates the company’s fundamentals 1/10.
22 October 2025

Stock Market Today

  • Centene Launches Community Programs Amid Depressed Stock Price: What Investors Should Know
    March 20, 2026, 6:30 AM EDT. Centene Corp subsidiaries have initiated community-focused programs targeting behavioral health, job training, housing support, and diabetes care, aiming to assist underserved populations across major U.S. markets. These efforts come as Centene shares (NYSE:CNC) remain under pressure, with a recent price of $35.57, down 13.7% in the past month and 40.3% over one year. Investors should monitor these initiatives closely for insights into Centene's regulatory relations and potential impact on medical loss ratios and membership retention. Despite current headwinds, the stock trades nearly 17% below analyst targets and is marked as undervalued by Simply Wall St. Key risks include rising costs without clear reimbursement or measurable health outcomes.
Go toTop